SCHEMBL15475147

SCHEMBL15475147

CS(=O)(=O)N1CCN(c2cc[c]c(Br)c2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.41
CYP2C9 P11712 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
ALDH1A1 P00352 3/20 0.41
POLB P06746 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 1/20 0.40
HPGD P15428 2/20 0.40
MAPK1 P28482 2/20 0.40
CYP2C19 P33261 2/20 0.40
HSD17B10 Q99714 2/20 0.40
USP2 O75604 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
THRB P10828 1/20 0.39
ABL1 P00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3132013 0.83 NPSR1 (0.49) MAPTCYP2C9NPSR1SMN1; SMN2ALDH1A1
SCHEMBL3139272 0.79 ACVR1B (0.46) MAPTCYP2C9NPSR1SMN1; SMN2ALDH1A1
SCHEMBL15475119 0.79 ADRA2C (0.47) MAPTSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL1810203 0.77 POLB (0.50) MAPTCYP2C9NPSR1SMN1; SMN2ALDH1A1
SCHEMBL6989683 0.77 TERT (0.40) MAPTNPSR1ALDH1A1POLBNPC1
SCHEMBL15474512 0.76 MAPT (0.42) MAPTSMN1; SMN2ALDH1A1POLBNPC1
SCHEMBL5744022 0.75 ALDH1A1 (0.42) MAPTNPSR1SMN1; SMN2ALDH1A1POLB
SCHEMBL1559291 0.75 NPY5R (0.56) MAPTCYP2C9NPSR1SMN1; SMN2ALDH1A1
SCHEMBL15474579 0.74 CHKA (0.45) MAPTSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL974007 0.74 POLB (0.54) MAPTCYP2C9SMN1; SMN2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021006267-A1 SALT OF PYRAZOLE DERIVATIVE AND PREPARATION OF PYRAZOLE DERIVATIVE グリーン・テック株式会社 2021-01-14 WO disclosed
WO-2020235582-A1 PREVENTIVE AND/OR THERAPEUTIC AGENT FOR MOTOR NEURON DISEASE グリーン・テック株式会社 (JP) 2020-11-26 WO disclosed
EP-3323816-A1 NOVEL PYRAZOLE DERIVATIVE Green Tech Co., Ltd. (JP) 2018-05-23 EP disclosed
US-9399635-B2 Pyrazole derivative GREEN TECH CO., LTD. (JP) 2016-07-26 US disclosed
US-20140088029-A1 NOVEL PYRAZOLE DERIVATIVE PHARMA EIGHT CO., LTD. (JP) 2014-03-27 US disclosed
EP-2698368-A1 NOVEL PYRAZOLE DERIVATIVE Pharma Eight Co. Ltd (JP) 2014-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088029-A1 NOVEL PYRAZOLE DERIVATIVE PSEN2, MAPT, PSEN1 MAPT 2/4885CYP2C9 4096/4885NPSR1 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.